Welcome to LookChem.com Sign In|Join Free

CAS

  • or

111822-93-6

111822-93-6

Post Buying Request

111822-93-6 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

111822-93-6 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 111822-93-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,1,1,8,2 and 2 respectively; the second part has 2 digits, 9 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 111822-93:
(8*1)+(7*1)+(6*1)+(5*8)+(4*2)+(3*2)+(2*9)+(1*3)=96
96 % 10 = 6
So 111822-93-6 is a valid CAS Registry Number.
InChI:InChI=1/C19H17Cl2NO4/c20-4-6-22(7-5-21)10-11-8-13-17(15(24)9-11)19(26)16-12(18(13)25)2-1-3-14(16)23/h1-3,8-9,23-24H,4-7,10H2

111822-93-6SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 18, 2017

Revision Date: Aug 18, 2017

1.Identification

1.1 GHS Product identifier

Product name 3-[bis(2-chloroethylamino)methyl]-1,8-dihydroxyanthracene-9,10-dione

1.2 Other means of identification

Product number -
Other names 9,10-Anthracenedione,3-[[bis(2-chloroethyl)amino]methyl]-1,8-dihydroxy

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:111822-93-6 SDS

111822-93-6Downstream Products

111822-93-6Relevant articles and documents

Novel Type of Potential Anticancer Agents Derived from Chrysophanol and Emodin. Some Structure-Activity Relationship Studies

Koyama, Masao,Kelly, T. Ross,Watanabe, Kyoichi A.

, p. 283 - 284 (1988)

-

Derivatives of chryosphanol

-

, (2008/06/13)

The present invention concerns compounds of the formula: STR1 wherein R1 hydrogen, a hydroxyl group or a methoxy group; R2 is hydrogen or a methyl group; R3 is hydrogen or a methyl group; Y is a halogen, a secondary amino group or a tertiary amino group; and Z is hydrogen or a halogen. The invention further concerns pharmaceutical compositions which comprises the above-identified compound or the acid salts thereof, and the use of the compound or compositions for treating a malignancy in a subject.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 111822-93-6